Follicular lymphoma: still Six characters in search of an author?

References

• Swerdlow S, Campo E, Harris N, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.
   Google Scholar
• Kojima M, Yamanaka S, Yoshida T, et al. Histological variety of floral variant of follicular lymphoma. APMIS 2006;114: 626–632.
   PubMed Web of Science ®Google Scholar
• Goates JJ, Kamel OW, LeBrun DP, Benharroch D, Dorfman RF. Floral variant of follicular lymphoma. Immunological and molecular studies support a neoplastic process. Am J Surg Pathol 1994;18:37–47.
   PubMed Web of Science ®Google Scholar
• Sotomayor EA, Shah IM, Sanger WG, Mark HF. In situ follicular lymphoma with a 14;18 translocation diagnosed by a multimodal approach. Exp Mol Pathol 2007;83:254–258.
   PubMed Web of Science ®Google Scholar
• Cong P, Raffeld M, Teruya-Feldstein J, Sorbara L, Pittaluga S, Jaffe ES. In situ localization of follicular lymphoma: description and analysis by laser capture microdissection. Blood 2002;99:3376–3382.
   PubMed Web of Science ®Google Scholar
• Cheung MC, Bailey D, Pennell N, et al. In situ localization of follicular lymphoma: evidence for subclinical systemic disease with detection of an identical BCL-2/IGH fusion gene in blood and lymph node. Leukemia 2009;23:1176–1179.
   PubMed Web of Science ®Google Scholar
• Schuler F, Dolken L, Hirt C, et al. Prevalence and frequency of circulating t(14;18)-MBR translocation carrying cells in healthy individuals. Int J Cancer 2009;124:958–963.
   PubMed Web of Science ®Google Scholar
• Roulland S, Lebailly P, Lecluse Y, Heutte N, Nadel B, Gauduchon P. Long-term clonal persistence and evolution of t(14;18)-bearing B cells in healthy individuals. Leukemia 2006;20:158–162.
   PubMed Web of Science ®Google Scholar
• Schmitt C, Balogh B, Grundt A, et al. The bcl-2/IgH rearrangement in a population of 204 healthy individuals: occurrence, age and gender distribution, breakpoints, and detection method validity. Leuk Res 2006;30:745–750.
   PubMed Web of Science ®Google Scholar
• Zignego AL, Giannelli F, Marrocchi ME, et al. t(14;18) translocation in chronic hepatitis C virus infection. Hepatology 2000;31:474–479.
   PubMed Web of Science ®Google Scholar
• Biagi JJ, Seymour JF. Insights into the molecular pathogenesis of follicular lymphoma arising from analysis of geographic variation. Blood 2002;99:4265–4275.
   PubMed Web of Science ®Google Scholar
• Gerard-Marchant R, Hamlin I, Lennert K, Rilke F, Stansfeld A, van Unnik J. Classification of non-Hodgkin’s lymhpoma. Lancet 1974;2:406.
   Web of Science ®Google Scholar
• Lennert K. Malignant lymphomas other than Hodgkin’s disease. New York: Springer-Verlag; 1978.
   Google Scholar
• Lennert K, Feller AC. Histopathology of non-Hodgkin’s lymphomas (based on the updated Kiel classification). Berlin: Springer-Verlag; 1992.
   Google Scholar
• Stansfeld AG, Diebold J, Noel H, et al. Updated Kiel classification for lymphomas. Lancet 1988;1:292–293.
   PubMed Web of Science ®Google Scholar
• Klapper W, Hoster E, Rolver L, et al. Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: the German Low Grade Lymphoma Study Group. J Clin Oncol 2007;25:3330–3336.
   PubMed Web of Science ®Google Scholar
• Silberman S, Fresco R, Steinecker PH. Signet ring cell lymphoma. A report of a case and review of the literature. Am J Clin Pathol 1984;81:358–363.
   PubMed Web of Science ®Google Scholar
• Pileri S, Serra L, Govoni E, Martinelli G. Signet ring cell lymphoma: a case report. Histopathology 1981;5:165–173.
   PubMed Web of Science ®Google Scholar
• Navas-Palacios JJ, Valdes MD, Lahuerta-Palacios JJ. Signet-ring cell lymphoma. Ultrastructural and immunohistochemical features of three varieties. Cancer 1983;52:1613–1623.
   PubMed Web of Science ®Google Scholar
• Harris M, Eyden B, Read G. Signet ring cell lymphoma: a rare variant of follicular lymphoma. J Clin Pathol 1981;34:884–891.
   PubMed Web of Science ®Google Scholar
• Pileri S, Rivano MT, Gobbi M, Taruscio D, Lennert K. Neoplastic and reactive follicles within B-cell malignant lymphomas. A morphological and immunological study of 30 cases. Hematol Oncol 1985;3:243–260.
   PubMed Web of Science ®Google Scholar
• Robetorye RS, Bohling SD, Medeiros LJ, Elenitoba-Johnson KS. Follicular lymphoma with monocytoid B-cell proliferation: molecular assessment of the clonal relationship between the follicular and monocytoid B-cell components. Lab Invest 2000;80:1593–1599.
   PubMed Web of Science ®Google Scholar
• Weiss RL, Ashwood ER, Kjeldsberg CR. Multilobated B-cell lymphoma. A clinicopathologic study of 24 cases. Arch Pathol Lab Med 1990;114:28–33.
   PubMed Web of Science ®Google Scholar
• Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84:1361–1392.
   PubMed Web of Science ®Google Scholar
• Piccaluga PP, Califano A, Klein U, et al. Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas. Haematologica 2008;93:1033–1038.
   PubMed Web of Science ®Google Scholar
• Colombat P, Brousse N, Morschhauser F. Single treatment with rituximab monotherapy for low-tumor burden follicular lymphoma (FL): survival analyses with extended follow-up of 7 years. Blood 2006;108(Suppl. 1): Abstract 486.
   Google Scholar
• Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004;103:4416–4423.
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin’s lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005;23:1088–1095.
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106:3725–3732.
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417–1423.
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825–2833.
   PubMed Web of Science ®Google Scholar
• Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007;25:1986–1992.
   PubMed Web of Science ®Google Scholar
• Salles G, Mounier N, de Guibert S. Rituximab combined with chemotherapy and interferon in folicular lymphoma patients: final analysis of the GELA-GOELAMS FL2000 study with a 5-year follow-up. Blood 2007;110(Suppl. 1): Abstract 792.
   Google Scholar
• Advani R, Forero-Torres A, Furman RR, et al. SGN-40 (anti-HuCO40 mAb) monotherapy induces durable objective responses in patiens with relapsed aggressive non-Hodgkin’s lymphoma: evidence of antitumor activity tram a phase I study. Blood 2006;108(Suppl. 1): Abstract 695.
   Google Scholar
• Gordon LI, Witzig TE, Molina A, Czuczman M, Emmanouilides C, Joyce R. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymphoma 2004;5:98–101.
   PubMedGoogle Scholar
• Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. J Clin Oncol 2002;20:3262–3269.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Molina A, Gordon LI, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 2007;109:1804–1810.
   PubMed Web of Science ®Google Scholar
• Pittaluga S, Ayoubi TA, Wlodarska I, et al. BCL-6 expression in reactive lymphoid tissue and in B-cell non-Hodgkin’s lymphomas. J Pathol 1996;179:145–150.
   PubMed Web of Science ®Google Scholar
• Natkunam Y, Zhao S, Mason DY, et al. The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas. Blood 2007;109:1636–1642.
   PubMed Web of Science ®Google Scholar
• Dogan A, Bagdi E, Munson P, Isaacson PG. CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol 2000;24:846–852.
   PubMed Web of Science ®Google Scholar
• Greeve J, Philipsen A, Krause K, et al. Expression of activation-induced cytidine deaminase in human B-cell non-Hodgkin lymphomas. Blood 2003;101:3574–3580.
   PubMed Web of Science ®Google Scholar
• Falini B, Fizzotti M, Pileri S, Liso A, Pasqualucci L, Flenghi L. Bcl-6 protein expression in normal and neoplastic lymphoid tissues. Ann Oncol 1997;8(Suppl. 2):101–104.
   PubMed Web of Science ®Google Scholar
• Karube K, Guo Y, Suzumiya J, et al. CD10-MUM1+ follicular lymphoma lacks BCL2 gene translocation and shows characteristic biologic and clinical features. Blood 2007;109: 3076–3079.
   PubMed Web of Science ®Google Scholar
• Naresh KN. MUM1 expression dichotomises follicular lymphoma into predominantly, MUM1-negative low-grade and MUM1-positive high-grade subtypes. Haematologica 2007;92:267–268.
   PubMed Web of Science ®Google Scholar
• Dogan A, Du MQ, Aiello A, et al. Follicular lymphomas contain a clonally linked but phenotypically distinct neoplastic B-cell population in the interfollicular zone. Blood 1998;91:4708–4714.
   PubMed Web of Science ®Google Scholar
• Barry TS, Jaffe ES, Kingma DW, et al. CD5+ follicular lymphoma: a clinicopathologic study of three cases. Am J Clin Pathol 2002;118:589–598.
   PubMed Web of Science ®Google Scholar
• Dong HY, Gorczyca W, Liu Z, et al. B-cell lymphomas with coexpression of CD5 and CD10. Am J Clin Pathol 2003; 119:218–230.
   PubMed Web of Science ®Google Scholar
• Dono M, Cerruti G, Zupo S. The CD5+ B-cell. Int J Biochem Cell Biol 2004;36:2105–2111.
   PubMed Web of Science ®Google Scholar
• Luo JH, Matsushima AY, Chen R, Szabolcs MJ. Detection of CD5 antigen on B cell lymphomas in fixed, paraffin embedded tissues using signal amplification by catalyzed reporter deposition. Eur J Histochem 1998;42:31–39.
   PubMed Web of Science ®Google Scholar
• Tiesinga JJ, Wu CD, Inghirami G. CD5+ follicle center lymphoma. Immunophenotyping detects a unique subset of ‘floral’ follicular lymphoma. Am J Clin Pathol 2000;114:912–921.
   PubMed Web of Science ®Google Scholar
• Braziel RM, Shipp MA, Feldman AL, et al. Molecular diagnostics. Hematology Am Soc Hematol Educ Program 2003:279–293.
   PubMedGoogle Scholar
• Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334–336.
   PubMed Web of Science ®Google Scholar
• Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood 1996;88:386–401.
   PubMed Web of Science ®Google Scholar
• Schraders M, de Jong D, Kluin P, Groenen P, van Krieken H. Lack of Bcl-2 expression in follicular lymphoma may be caused by mutations in the BCL2 gene or by absence of the t(14;18) translocation. J Pathol 2005;205:329–335.
   PubMed Web of Science ®Google Scholar
• Masir N, Campbell LJ, Goff LK, et al. BCL2 protein expression in follicular lymphomas with t(14;18) chromosomal translocations. Br J Haematol 2009;144:716–725.
   PubMed Web of Science ®Google Scholar
• Masir N, Campbell LJ, Jones M, Mason DY. Pseudonegative BCL2 protein expression in a t(14;18) translocation positive lymphoma cell line: a need for an alternative BCL2 antibody. Pathology;42:212–216.
   PubMed Web of Science ®Google Scholar
• O’Shea D, O’Riain C, Taylor C, et al. The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. Blood 2008;112:3126–3129.
   PubMed Web of Science ®Google Scholar
• Koster A, Tromp HA, Raemaekers JM, et al. The prognostic significance of the intra-follicular tumor cell proliferative rate in follicular lymphoma. Haematologica 2007;92:184–190.
   PubMed Web of Science ®Google Scholar
• Martin AR, Weisenburger DD, Chan WC, et al. Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. Blood 1995;85:3671–3678.
   PubMed Web of Science ®Google Scholar
• Ott G, Katzenberger T, Lohr A, et al. Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. Blood 2002;99:3806–3812.
   PubMed Web of Science ®Google Scholar
• Wang SA, Wang L, Hochberg EP, Muzikansky A, Harris NL, Hasserjian RP. Low histologic grade follicular lymphoma with high proliferation index: morphologic and clinical features. Am J Surg Pathol 2005;29:1490–1496.
   PubMed Web of Science ®Google Scholar
• Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004;351:2159–2169.
   PubMed Web of Science ®Google Scholar
• Farinha P, Masoudi H, Skinnider BF, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005;106:2169–2174.
   PubMed Web of Science ®Google Scholar
• Carreras J, Lopez-Guillermo A, Fox BC, et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 2006;108:2957–2964.
   PubMed Web of Science ®Google Scholar
• Tzankov A, Meier C, Hirschmann P, Went P, Pileri SA, Dirnhofer S. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin’s lymphoma. Haematologica 2008;93:193–200.
   PubMed Web of Science ®Google Scholar
• Lee AM, Clear AJ, Calaminici M, et al. Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol 2006;24:5052–5059.
   PubMed Web of Science ®Google Scholar
• Carreras J, Lopez-Guillermo A, Roncador G, et al. High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J Clin Oncol 2009;27:1470–1476.
   PubMed Web of Science ®Google Scholar
• de Jong D, Koster A, Hagenbeek A, et al. Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols. Haematologica 2009;94:70–77.
   PubMed Web of Science ®Google Scholar
• Wahlin BE, Aggarwal M, Montes-Moreno S, et al. A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1--positive, regulatory, cytotoxic, and helper T cells and macrophages. Clin Cancer Res 2010;16:637–650.
   PubMed Web of Science ®Google Scholar
• Sweetenham JW, Goldman B, LeBlanc ML, et al. Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study. Ann Oncol;21:1196–1202.
   PubMed Web of Science ®Google Scholar
• Klein U, Dalla-Favera R. Germinal centres: role in B-cell physiology and malignancy. Nat Rev Immunol 2008;8:22–33.
   PubMed Web of Science ®Google Scholar
• Klein U, Tu Y, Stolovitzky GA, et al. Transcriptional analysis of the B cell germinal center reaction. Proc Natl Acad Sci USA 2003;100:2639–2644.
   PubMed Web of Science ®Google Scholar
• Ott G, Rosenwald A. Molecular pathogenesis of follicular lymphoma. Haematologica 2008;93:1773–1776.
   PubMed Web of Science ®Google Scholar
• Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985;228:1440–1443.
   PubMed Web of Science ®Google Scholar
• Tsujimoto Y, Gorham J, Cossman J, Jaffe E, Croce CM. The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 1985; 229:1390–1393.
   PubMed Web of Science ®Google Scholar
• Martinez-Climent JA, Fontan L, Gascoyne RD, Siebert R, Prosper F. Lymphoma stem cells: enough evidence to support their existence? Haematologica 2010;95:293–302.
   PubMed Web of Science ®Google Scholar
• Bende RJ, Smit LA, van Noesel CJ. Molecular pathways in follicular lymphoma. Leukemia 2007;21:18–29.
   PubMed Web of Science ®Google Scholar
• McDonnell TJ, Deane N, Platt FM, et al. Bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 1989;57:79–88.
   PubMed Web of Science ®Google Scholar
• Zelenetz AD, Chen TT, Levy R. Clonal expansion in follicular lymphoma occurs subsequent to antigenic selection. J Exp Med 1992;176:1137–1148.
   PubMed Web of Science ®Google Scholar
• Cattoretti G, Pasqualucci L, Ballon G, et al. Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell 2005; 7:445–455.
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Bereschenko O, Niu H, et al. Molecular pathogenesis of non-Hodgkin’s lymphoma: the role of Bcl-6. Leuk Lymphoma 2003;44(Suppl. 3):S5–S12.
   PubMed Web of Science ®Google Scholar
• Bosga-Bouwer AG, van den Berg A, Haralambieva E, et al. Molecular, cytogenetic, and immunophenotypic characterization of follicular lymphoma grade 3B; a separate entity or part of the spectrum of diffuse large B-cell lymphoma or follicular lymphoma? Hum Pathol 2006;37:528–533.
   PubMed Web of Science ®Google Scholar
• Oschlies I, Salaverria I, Mahn F, et al. Pediatric follicular lymphoma--a clinico-pathological study of a population-based series of patients treated within the Non-Hodgkin’s Lymphoma–Berlin-Frankfurt-Munster (NHL-BFM) multicenter trials. Haematologica 2010;95:253–259.
   PubMed Web of Science ®Google Scholar
• Leich E, Salaverria I, Bea S, et al. Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. Blood 2009; 114:826–834.
   PubMed Web of Science ®Google Scholar
• Bohen SP, Troyanskaya OG, Alter O, et al. Variation in gene expression patterns in follicular lymphoma and the response to rituximab. Proc Natl Acad Sci USA 2003; 100: 1926–1930.
   PubMed Web of Science ®Google Scholar
• Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med 2006;354:2431–2442.
   PubMed Web of Science ®Google Scholar
• Glas AM, Kersten MJ, Delahaye LJ, et al. Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood 2005;105: 301–307.
   PubMed Web of Science ®Google Scholar
• Lossos IS, Alizadeh AA, Diehn M, et al. Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proc Natl Acad Sci USA 2002; 99:8886–8891.
   PubMed Web of Science ®Google Scholar
• Carlotti E, Wrench D, Matthews J, et al. Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone. Blood 2009;113:3553–3557.
   PubMed Web of Science ®Google Scholar
• MacLennan IC. Germinal centers still hold secrets. Immunity 2005;22:656–657.
   PubMed Web of Science ®Google Scholar
• Allen CD, Okada T, Cyster JG. Germinal-center organization and cellular dynamics. Immunity 2007;27:190–202.
   PubMed Web of Science ®Google Scholar
• Allen CD, Okada T, Tang HL, Cyster JG. Imaging of germinal center selection events during affinity maturation. Science 2007;315:528–531.
   PubMed Web of Science ®Google Scholar